Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran.
Pablo ZubiaurMiriam Saiz-RodríguezDolores OchoaMarcos Navares-GómezGina MejíaManuel RománDora KollerPaula Soria-ChacarteguiSusana AlmenaraFrancisco Abad-SantosPublished in: Advances in therapy (2020)
Sex, concomitant use of pantoprazole and SLC22A1, CYP2D6 and CYP3A5 polymorphism had an effect on dabigatran pharmacokinetics and safety. Previously published pharmacogenetic predictors, namely CES1 or ABCB1 polymorphisms, had no effect on pharmacokinetics and safety. This study is of interest as it increases the scarce pharmacogenetic information on dabigatran.